Angong Niuhuang Pill

PreclinicalSmall molecule

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Angong Niuhuang Pill is one of 31 small molecule programs targeting Inflammatory Response. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory ResponseActive, not recruiting

Inflammatory ResponsePreclinical

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Inflammatory Response

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

3 2

MS Contin

HHikma Pharmaceuticals LLC

Approved

3 3

Versed

CConrado Roberto Hoffmann Filho

Approved

2 4

Advil

KKenvue Brands

Approved

2 5

Andriol

AAuxilium

Approved

1 6

Zocor

OOrganon and Co

Approved

1 7

Clozaril

LLife Extension Foundation Inc.

Approved

1 8

Singulair

OOrganon and Co

Approved

1 9

Oxycontin

PProtega

Approved

1 10

Sufenta

LLeaf Vertical Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalNot yet recruiting

Acute Ischemic Stroke

NCT07882030

Clinical

Trials by Indication[1]

Inflammatory Response1 trial

Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery

Not yet recruiting·NNanjing Medical University·N/A·NCT06723366·120 enrolled

Cognitive impairment1 trial

Clinical Study of Angong Niuhuang Pill and Acupuncture on PSCI Angong Niuhuang Pill Combined With Supervised Pulse Music Electroacupuncture on Cognitive Impairment After Ischemic Stroke

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT05731310·65 enrolled

Acute Ischemic Stroke1 trial

Efficacy and Safety of Early Administration of Angong Niuhuang Pill in Patients With Disabling Acute Ischemic Stroke: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Not yet recruiting·XXuanwu Hospital, Beijing·Preclinical·NCT07882030·1,200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Angong Niuhuang Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Angong Niuhuang Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Angong Niuhuang Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Angong Niuhuang Pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Inflammatory Response1 trial

Cognitive impairment1 trial

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News